ClinicalTrials.gg
Active, not recruitingNCT07388589SOLOSUpdated Nov 18, 2026

Soluble and Osmotic Fibre (SOLOS) Diet for Constipation

An observational study in Constipation, Constipation - Functional and Constipation Chronic Idiopathic, sponsored by Singapore Institute of Technology. Active, not recruiting at 1 site in Singapore. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Singapore Institute of Technology · Observational

How we know

Updated Nov 18, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
180
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This research aims to study the dual effectiveness of incorporating soluble fibre and osmotic carbohydrates (SOLOS), with or without restricting fructans and GOS, and present novel findings in managing GI symptoms in patients with functional bowel disorders with constipation. These findings may also support researchers and clinicians in shaping new dietary approaches in the management of general constipation symptoms.

Read the detailed description

Aims: This retrospective clinical audit study aims to evaluate the effectiveness of dietary advice promoting increased intake of soluble fibre and poorly absorbed (osmotic) carbohydrates, with or without restriction of fructans and galacto-oligosaccharides (GOS), on adult patients (18-70 years old) with functional bowel disorders with constipation from the UK by comparing to baseline scores for severity and frequency of gastrointestinal symptoms and stool output.

Hypothesis: The dietary advice promoting increased intake of soluble fibre and osmotic sugars will produce a significant change from baseline in gastrointestinal symptoms and stool output in adult patients (18-70 years old) with functional bowel disorders with constipation from the UK.

Methodology: The study population will include all patients who have consulted with the Principal Investigator, a specialist gastroenterology dietitian between January 2021 and December 2025. All patients who have met the inclusion criteria will then form the research sample. Eligible subjects' data and study variables will be extracted from patient letters and clinical management records without direct patient contact. These study variables include the frequency and severity of the patients' symptoms at their initial appointment and follow-up appointment if available. Anthropometric data such as height and weight will also be obtained. The compiled data will then be analysed by conducting statistical tests, specifically the paired t-test, which will produce descriptive statistics that will interpret the effectiveness of the SOLOS diet on patients with functional bowel disorders with constipation.

Applications: To date, there has not been any study studying the dual effects of soluble fibre and osmotic carbohydrates consumption on alleviating constipation-related symptoms in patients with functional bowel disorders with constipation. Therefore, this research aims to present novel findings that can advance existing dietary management of functional bowel disorders with constipation. These results are expected to deepen understanding and research in food manufacturing and clinical nutrition.

02

Conditions studied

  • Constipation
  • Constipation - Functional
  • Constipation Chronic Idiopathic
  • Constipation Predominant Irritable Bowel Syndrome
  • Constipation, Signs and Symptoms, Digestive
  • Constipation-predominant IBS (IBS-C)
  • Constipation-predominant Irritable Bowel Syndrome
  • Constipation-predominant Irritable Bowel Syndrome (IBS-C)
  • Diet Therapy
  • Diet Modification
  • Diet, Food and Nutrition
  • Dietary and Nutritional Therapies
  • Dietary Fiber
  • Dietary Fibers

Browse trials for

Keywords

  • Constipation
  • Functional constipation
  • Constipation-predominant irritable bowel syndrome (IBS-C)
  • Soluble fiber
  • osmotic sugar
03

In context

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

This study's planned enrollment of 180 is above the median of 120 across 126 observational studies indexed under Constipation.

Browse Constipation studies →

Lead sponsor

Singapore Institute of Technology is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (18-70 years old) with functional bowel disorders with constipation from the UK, seen by a specialist dietitian (Principal Investigator)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presented with symptoms of FC, IBS-C, or SIBO-C
  • Were aged 18 to 70 years old. (Research focus is on adult patients, excluding older adults and children)
  • Date of baseline (first) and follow-up appointments ranged from January 2021 to December 2025
  • Did not attend follow-up appointments (Data would be treated as "intention to treat" and data points were carried forward for conservative analysis).

Exclusion criteria

Exclusion Criteria:

  • Had no history of constipation-related symptoms (Does not relate to research question's population or outcome)
  • Started treatment before January 2021
  • Were not due for follow-up before the end of December 2025
  • Symptom and stool data inadequately recorded
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Functional Constipation

    Other: Diet

  • Patients with IBS-C or SIBO-C

    Other: Diet

Interventions

  • OtherDiet

    Dietary advice combining increased intake of dietary sources of soluble fibres and osmotic sugars in improving constipation symptoms.

    Also known as: soluble fibre and osmotic carbohydrates diet, soluble fibre and osmotic carbohydrates (SOLOS) diet, SOLOS diet

06

What researchers measure

Primary outcomes

  1. Stool frequency

    Frequency of stool output per week

    Time frame: January 2021 to December 2025

  2. Stool form

    Bristol Stool Form Scale

    Time frame: January 2021 to December 2025

  3. Gastrointestinal Symptom Frequency

    Frequency of gastrointestinal symptom in a week, recorded as number of days out of 7 the symptom occurred over the past week.

    Time frame: January 2021 to December 2025

  4. Gastrointestinal Symptom Severity

    Severity of symptoms in a week scored using Gastrointestinal Symptom Rating Scale (GSRS). Scores range from 0 (absent) to 3 (severe).

    Time frame: January 2021 to December 2025

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 5, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Active, not recruiting
    + 2 other changes: date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07388589
Lead sponsor
Singapore Institute of Technology
Responsible party
Wilson Bridgette Jane (Assistant Professor, Singapore Institute of Technology) — Principal investigator
First posted
Feb 5, 2026
Start date
Feb 2, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Bridgette J Wilson, Dr
principal investigator · Singapore Institute of Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion